Acceleron Pharma Inc.
ALK7 ANTAGONISTS AND USES THEREOF
Last updated:
Abstract:
In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
Status:
Application
Type:
Utility
Filling date:
22 Mar 2019
Issue date:
13 Feb 2020